赵敬慈+刘静

[摘要]目的 探讨雾化吸入布地奈德在小儿肺炎支原体肺炎患儿中的应用效果。方法 选择2013年8月～2016年5月我院收治的小儿肺炎支原体肺炎患儿75例，将所有入选患儿分为治疗组（n=40）和对照组（n=35）。两组患儿在常规治疗的基础上，给予治疗组的患儿阿奇霉素和雾化吸入布地奈德混悬液治疗，而对照组患儿仅接受阿奇霉素治疗，结束后比较两组患儿的治疗效果。结果 治疗组患儿治疗后的总有效率（97.5%）明显高于对照组患儿（82.9%）；治疗组患儿的体温恢复正常、哮鸣音消失、咳嗽消失及湿啰音消失的时间均短于对照组患儿；治疗组不良反应的发生率（5.0%）明显低于对照组（20.0%）；两组比较差异均有统计学意义（P<0.05）。结论 雾化吸入布地奈德治疗小儿肺炎支原体肺炎临床效果显著，不良反应少，安全有效，值得在临床推广。

[关键词]小儿；肺炎支原体肺炎；雾化吸入；布地奈德；疗效

[中图分类号] R563.1 [文献标识码] A [文章编号] 1674-4721（2016）12（c）-0073-03

Effect observation of Budesonide Inhalation in the treatment of Mycoplasma pneumonia

ZHAO Jing-ci LIU Jing

Department of Pediatrics，the First People′s Hospital of Shunde Affiliated Chencun Hospital，Guangdong Province，Foshan 528313，China

[Abstract]Objective To investigate the curative effect of nebulized Budesonide in the treatment of children with Mycoplasma pneumoniae pneumonia.Methods 75 children with Mycoplasma pneumonia pneumonia in our hospital from August 2013 to May 2016 were selected and divided into the treatment group（n=40） and control group（n=35）.The two groups were treated with the conventional treatment，and the treatment group was given the treatment of Azithromycin and Budesonide Atomization Inhalation in addition，while the control group was treated only by Azithromycin.After the treatment，the effect of the two groups was compared.Results In the treatment group，the effective rate （97.5%） was significantly higher than that in the control group （82.9%）. The time of body temperature returned to normal，wheeze disappeared，and moist rales disappeared，cough weire disappeared in the treatment group was shorter than that of the control group；the incidence of adverse reactions in the treatment group （5.0%） was significantly lower than that in the control group （20.0%）；the differences between the two groups were statistically significant （P<0.05）.Conclusion Budesonide Inhalation in the treatment of Mycoplasma pneumonia has significant clinical effect.It has less adverse reaction，safe and effective，and is worth in clinical promotion.

[Key words]Children；Mycoplasma pneumoniae pneumonia；Atomizing inhalation；Budesonide；Curative effect

支原体肺炎是由机体感染肺炎支原体引起肺部炎性改变造成的，在临床上常常表现为咳嗽、发热、气促、呼吸障碍、肺部啰音等不良症状[1]。目前，肺炎支原体肺炎（Mycoplasma pneumoniae pneumonia，MPP）在儿童肺炎中出现的比例逐年增多，占支气管肺炎总数的10%～20%，其潜伏期为2～3周，是儿童呼吸道感染的常见疾病之一[2]。肺炎支原体是无菌培养的基础上能独立存活的最小微生物，通常由急性期的飞沫经呼吸道吸入感染机体，可以引起局部散发或小流行传播，特别是易发生在幼儿园或学校等重点区域[3]。近年来，雾化吸入治疗是小儿肺炎支原体肺炎的临床常用治疗方式，它能使患儿较快地吸收药物，充分发挥药物的治疗作用[4]。……